Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study
Autor: | Francesco Borgia, Consalvo Mattia, Ivan Gentile, Riccardo Scotto, Pasquale Ambrosino, Biagio Pinchera, Matteo Nicola Dario Di Minno, Ilenia Calcaterra, Antonio Riccardo Buonomo, Manuel Crispo |
---|---|
Přispěvatelé: | Di Minno, M. N. D., Ambrosino, P., Buonomo, A. R., Pinchera, B., Calcaterra, ILENIA LORENZA, Crispo, M., Scotto, R., Borgia, F., Mattia, C., Gentile, I. |
Rok vydání: | 2019 |
Předmět: |
Liver Cirrhosis
Male medicine.medical_specialty Cirrhosis Direct-acting antiviral agent Hepatitis C virus Cardiovascular risk factors Hepacivirus 030204 cardiovascular system & hematology medicine.disease_cause DIRECT ACTING ANTIVIRALS Chronic hepatitis C Risk profile Gastroenterology Antiviral Agents Cohort Studies 03 medical and health sciences 0302 clinical medicine Chronic hepatitis Internal medicine Internal Medicine medicine Humans In patient 030212 general & internal medicine Endothelium Prospective Studies Prospective cohort study Aged Hepatitis Chronic business.industry Endothelial function chronic hepatitis C direct-acting antiviral agents endothelial function Middle Aged Protective Factors medicine.disease Hepatitis C Italy Emergency Medicine Female business |
Zdroj: | Internal and emergency medicine. 15(2) |
ISSN: | 1970-9366 |
Popis: | Hepatitis C virus (HCV) infection is associated with increased cardiovascular risk. We evaluated effects of direct-acting antiviral agents (DAAs) on flow-mediated dilation (FMD), a recognized marker of cardiovascular risk. We evaluated FMD and post-ischemic hyperemia (PIH) in consecutive HCV out-patients before starting DAAs, at the end of treatment (Teot) and 12 weeks thereafter. In 22 HCV subjects (age 64.0 years), baseline FMD was 4.52% ± 1.90 and PIH of 5814.4 (IQR 3786.9–7861.9). At (Teot), all patients showed undetectable levels of HCV-RNA and FMD changed from 4.52% ± 1.90 to 9.39% ± 4.06 (p |
Databáze: | OpenAIRE |
Externí odkaz: |